Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.
NCT ID: NCT04213664
Last Updated: 2020-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
4666 participants
OBSERVATIONAL
2019-12-31
2020-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospective Cohort Study
NCT06883565
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
NCT02105168
Evaluation of Diagnostic Value of Molecular Markers in Renal Cancer
NCT00491621
Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma
NCT01374672
Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer
NCT05285579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All analyzes will be based on previously published studies. For this reason, patient consent and ethical approval will not be required.
An exhaustive search will be conducted in PubMed, Science Direct and Cochrane Database of Systematic Reviews for eligible studies that explored the prognostic role of LMR in patients with localized renal tumors, who underwent to partial or radical nephrectomy from January 1965 to July 2019. The terms search will include: "monocyte lymphocyte ratio", "renal cancer", "prognosis".
Cohort studies or observational studies will be included, patients with localized renal tumors who underwent partial or radical nephrectomy, with histopathologically confirmed neoplasms, who had access to the full text and without language limitation.
Inclusion:
Any observational study (cross-sectional, case-control, longitudinal with cross-sectional data) will be included.
Patients with localized renal tumors who underwent partial or radical nephrectomy, with histopathologically confirmed neoplasms, who had access to the full text and without language limitation will be included.
Exclusion: Reviews, case reports, conference abstracts, letters, animal or cell studies.
Relevant articles will be identified in duplicate by two independent reviewers by first screening the titles and abstracts followed by the full text against inclusion and exclusion criteria. Any disagreement will be resolved by consensus with a third reviewer experienced in the renal cancer management.
The studies reflected the hazard ratio (HR) and corresponding 95% confidence intervals (CI), in which the overall survival (OS), specific cancer specific survival (CSS), recurrence-free survival (RFS), disease-free survival (DFS) and progression-free survival (PFP).
Information will be extracted for the first author, publication year, geographic location, study design, patient information (sample size, mean/median age, sex distribution, performance status), LMR, endpoint (OS, CSS, RFS, DFS, PFS), therapy, follow up duration, multivariate factors, hazard ratio (HR) and corresponding 95% confidence intervals (CIs), or exact P values. When univariate HR and multivariate HR were both reported, only the multivariate HR will be used.
OS is defined as the interval from the date of surgery in the primary tumor until death. CSS is defined as the interval from the date of surgery in the primary tumor to death for urological tumors. RFS is defined as the interval from the date of surgery in the primary tumor to local, regional or distant recurrence or death from any cause. DFS is defined as the interval from the date of surgery in the primary tumor to local, regional or distant recurrence. PFS is defined as the interval from the date of surgery in the primary tumor to the progression of the disease (including local recurrence or distant metastasis) or death.
The Newcastle-Ottawa Scale (NOS) will be used to assess the quality of studies. A maximum of 9 points can be given for each study in the categories of: selection of patients, comparability of the study groups, and assessment of outcomes. We will define high-quality studies with scores \>7.
If the necessary data are available, subgroup analyses will be performed to explore the potential sources of heterogeneity according to country, analysis type, tumor type, sample size and cut-off value.
Statistical study:
Data will be combined using random effect models. The Cochrane χ² (Cochrane Q) statistic and the I² test will be used to analyze heterogeneity.
Before calculating the combined results for all trials, statistical heterogeneity will be evaluated by using the I² statistic and p-value, which assessed the appropriateness of pooling the individual study results. The I² value provided an estimate of the amount of variance across studies because of heterogeneity rather than chance. I² values of 25%, 50%, and 75% corresponded to low, moderate, and high levels of heterogeneity, respectively. If p\> 0.05, the heterogeneity will be not substantial. Thus, a fixed-effect model will be used to calculate forest plots. If p \< 0.05, however, the heterogeneity will be considered substantial. Then a random effects models were used.
The publication bias will be graphically explored through funnel plot, and Duval and Tweedie's "trim-and-fill" test will be used to correct possible publication bias.
Statistical significance was defined as p less than 0.05.
Statistics will done using R 3.5.0 (R Core Team, 2018) and the meta (v4.1-5; Schwarzer, Guido, 2019) package.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non-metastatic renal cell carcinoma
Pretreatment lymphocyte to monocyte ratio in non-metastatic patients with renal cell
prognosis
cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prognosis
cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No restrictions to date or language will be applied.
* Cohort or observational studies in patients with non-metastatic renal cell carcinoma who underwent radical or partial nephrectomy, with hazard ratios (HR) and corresponding 95% confidence intervals (CI) that assessed association between LMR and overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and disease-free survival (DFS) will be analyzed.
* -There were no restrictions about gender and ethnicity.
Exclusion Criteria
* Patients were diagnosed non-metastatic renal cell carcinoma, but without standard treatments (Ablative therapy).
* Preoperative inflammatory markers were not measured.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Corporacion Parc Tauli
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dario Garcia-Rojo
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Garcia-Rojo
Role: PRINCIPAL_INVESTIGATOR
Corporacion Parc Tauli.Sabadell. Spain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Corporacion Parc Tauli
Sabadell, Outside U.S./Canada, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Li J, Cheng Y, Ji Z. Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2019 Jan;98(2):e14091. doi: 10.1097/MD.0000000000014091.
Grimes N, Tyson M, Hannan C, Mulholland C. A Systematic Review of the Prognostic Role of Hematologic Scoring Systems in Patients With Renal Cell Carcinoma Undergoing Nephrectomy With Curative Intent. Clin Genitourin Cancer. 2016 Aug;14(4):271-6. doi: 10.1016/j.clgc.2016.01.006. Epub 2016 Jan 22.
Wang X, Su S, Guo Y. The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017 Sep 20;8(48):84506-84514. doi: 10.18632/oncotarget.21108. eCollection 2017 Oct 13.
Hutterer GC, Stoeckigt C, Stojakovic T, Jesche J, Eberhard K, Pummer K, Zigeuner R, Pichler M. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma. Urol Oncol. 2014 Oct;32(7):1041-8. doi: 10.1016/j.urolonc.2014.04.001. Epub 2014 Jul 11.
Chang Y, Fu Q, Xu L, Zhou L, Liu Z, Yang Y, Lin Z, Xu J. Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma. Tumour Biol. 2016 Apr;37(4):4613-20. doi: 10.1007/s13277-015-4300-7. Epub 2015 Oct 27.
Xia WK, Wu X, Yu TH, Wu Y, Yao XJ, Hu H. Prognostic significance of lymphocyte-to-monocyte ratio and CRP in patients with nonmetastatic clear cell renal cell carcinoma: a retrospective multicenter analysis. Onco Targets Ther. 2016 May 9;9:2759-67. doi: 10.2147/OTT.S101458. eCollection 2016.
Garcia-Rojo D, Prera A, Munoz-Rodriguez J, Oliva JC, Dominguez A, Prats J. Prognostic value of lymphocyte-to-monocyte ratio previously determined to surgery in patients with non-metastatic renal cell carcinoma: A systematic review and a prisma-compliant meta-analysis. Medicine (Baltimore). 2021 Jan 22;100(3):e24152. doi: 10.1097/MD.0000000000024152.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019/679
Identifier Type: REGISTRY
Identifier Source: secondary_id
CSPT-URO-2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.